Eric B. Harstad

1000 total citations
21 papers, 653 citations indexed

About

Eric B. Harstad is a scholar working on Oncology, Molecular Biology and Health, Toxicology and Mutagenesis. According to data from OpenAlex, Eric B. Harstad has authored 21 papers receiving a total of 653 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Molecular Biology and 4 papers in Health, Toxicology and Mutagenesis. Recurrent topics in Eric B. Harstad's work include Trace Elements in Health (4 papers), Heavy Metal Exposure and Toxicity (4 papers) and HER2/EGFR in Cancer Research (3 papers). Eric B. Harstad is often cited by papers focused on Trace Elements in Health (4 papers), Heavy Metal Exposure and Toxicity (4 papers) and HER2/EGFR in Cancer Research (3 papers). Eric B. Harstad collaborates with scholars based in United States, Australia and China. Eric B. Harstad's co-authors include Curtis D. Klaassen, Christopher A. Bradfield, Jacqueline A. Walisser, Maureen K. Bunger, Edward Glover, Melissa M. Schutten, S.J. Enna, Kenneth E. McCarson, Dolores Diaz and Jason Boggs and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Clinical Cancer Research.

In The Last Decade

Eric B. Harstad

20 papers receiving 624 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric B. Harstad United States 15 238 170 153 75 71 21 653
Karen E. Weis United States 10 323 1.4× 146 0.9× 130 0.8× 41 0.5× 64 0.9× 19 907
Shouting Liu China 14 365 1.5× 156 0.9× 81 0.5× 72 1.0× 56 0.8× 18 716
P. James Scrivens Canada 7 520 2.2× 59 0.3× 110 0.7× 56 0.7× 87 1.2× 7 768
Shu-Jun Chiu Taiwan 15 339 1.4× 149 0.9× 59 0.4× 26 0.3× 91 1.3× 22 685
Rossana La Sorda Italy 16 418 1.8× 377 2.2× 60 0.4× 78 1.0× 110 1.5× 18 1.1k
William Y. Chang United States 17 483 2.0× 80 0.5× 75 0.5× 33 0.4× 69 1.0× 28 1.1k
Brad Saville United States 7 488 2.1× 194 1.1× 226 1.5× 16 0.2× 133 1.9× 7 1.0k
A. Yu. Grishanova Russia 12 172 0.7× 122 0.7× 56 0.4× 37 0.5× 51 0.7× 66 486
Daniela Montanaro Italy 9 344 1.4× 168 1.0× 36 0.2× 54 0.7× 148 2.1× 10 856

Countries citing papers authored by Eric B. Harstad

Since Specialization
Citations

This map shows the geographic impact of Eric B. Harstad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric B. Harstad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric B. Harstad more than expected).

Fields of papers citing papers by Eric B. Harstad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric B. Harstad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric B. Harstad. The network helps show where Eric B. Harstad may publish in the future.

Co-authorship network of co-authors of Eric B. Harstad

This figure shows the co-authorship network connecting the top 25 collaborators of Eric B. Harstad. A scholar is included among the top collaborators of Eric B. Harstad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric B. Harstad. Eric B. Harstad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Neff‐LaFord, Haley D., Nancy Everds, Steven Duniho, et al.. (2024). The Vedotin Antibody–Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles. Molecular Cancer Therapeutics. 23(10). 1483–1493. 10 indexed citations
2.
Maher, Jonathan, Rui Zhang, Gopinath S. Palanisamy, et al.. (2022). Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition. Toxicology and Applied Pharmacology. 438. 115905–115905. 7 indexed citations
3.
Hardwick, Rhiannon N., Patrick Brassil, Ilaria Badagnani, et al.. (2022). Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species. Toxicological Sciences. 186(2). 323–337. 10 indexed citations
4.
Wang, Xiaojing, Aleksandr Kolesnikov, Suzanne Tay, et al.. (2017). Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability. Journal of Medicinal Chemistry. 60(10). 4458–4473. 19 indexed citations
5.
Harstad, Eric B., Jessica A. Couch, Xiao Ding, et al.. (2016). Balancing Blood Sample Volume with 3Rs: Implementation and Best Practices for Small Molecule Toxicokinetic Assessments in Rats. ILAR Journal. 57(2). 157–165. 14 indexed citations
6.
Zhong, Yu, Paula Katavolos, Tien‐Trung Nguyen, et al.. (2015). Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1. Toxicologic Pathology. 44(2). 267–278. 69 indexed citations
7.
Lin, Kedan, Bonnee Rubinfeld, Crystal Zhang, et al.. (2015). Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers. Clinical Cancer Research. 21(22). 5139–5150. 65 indexed citations
8.
Harstad, Eric B., Jonathan S. Rosenblum, Mark D. Gorrell, et al.. (2013). DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues. Regulatory Peptides. 186. 26–35. 15 indexed citations
9.
Wang, Xiaojing, Steven Magnuson, Huiyong Hu, et al.. (2013). Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design. Bioorganic & Medicinal Chemistry Letters. 23(11). 3149–3153. 55 indexed citations
10.
Poulin, Patrick, Donna M. Dambach, Kevin A. Ford, et al.. (2013). An Algorithm for Evaluating Potential Tissue Drug Distribution in Toxicology Studies from Readily Available Pharmacokinetic Parameters. Journal of Pharmaceutical Sciences. 102(10). 3816–3829. 9 indexed citations
11.
Lin, Kedan, Crystal Zhang, Eric B. Harstad, et al.. (2013). Abstract 5619: Preclinical development of anti-SLC34A2 antibody drug conjugate as a therapeutic for non-small cell lung and ovarian cancers.. Cancer Research. 73(8_Supplement). 5619–5619.
12.
Diaz, Dolores, Kevin A. Ford, Dylan P. Hartley, et al.. (2012). Pharmacokinetic drivers of toxicity for basic molecules: Strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor. Toxicology and Applied Pharmacology. 266(1). 86–94. 22 indexed citations
13.
14.
Liederer, Bianca M., Xingrong Liu, Leonid M. Berezhkovskiy, et al.. (2011). Preclinical stereoselective disposition and toxicokinetics of two novel MET inhibitors. Xenobiotica. 42(5). 456–465. 1 indexed citations
15.
Harstad, Eric B., et al.. (2006). Liver Deformation in Ahr-Null Mice: Evidence for Aberrant Hepatic Perfusion In Early Development. Molecular Pharmacology. 69(5). 1534–1541. 49 indexed citations
16.
Walisser, Jacqueline A., Maureen K. Bunger, Edward Glover, Eric B. Harstad, & Christopher A. Bradfield. (2004). Patent Ductus Venosus and Dioxin Resistance in Mice Harboring a Hypomorphic Arnt Allele. Journal of Biological Chemistry. 279(16). 16326–16331. 102 indexed citations
17.
Harstad, Eric B. & Curtis D. Klaassen. (2002). iNOS-null mice are not resistant to cadmium chloride-induced hepatotoxicity. Toxicology. 175(1-3). 83–90. 31 indexed citations
18.
Harstad, Eric B. & Curtis D. Klaassen. (2002). Tumor Necrosis Factor-α-Null Mice Are Not Resistant to Cadmium Chloride-Induced Hepatotoxicity. Toxicology and Applied Pharmacology. 179(3). 155–162. 29 indexed citations
19.
Harstad, Eric B.. (2002). Analysis of Strain Difference in Sensitivity to Cadmium-Induced Hepatotoxicity in Fischer 344 and Sprague-Dawley Rats. Toxicological Sciences. 67(2). 329–340. 26 indexed citations
20.
Enna, S.J., Eric B. Harstad, & Kenneth E. McCarson. (1998). Regulation of neurokinin-1 receptor expression by GABAB receptor agonists. Life Sciences. 62(17-18). 1525–1530. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen E. Weis Breakdown of academic impact, for papers by Shouting Liu Breakdown of academic impact, for papers by P. James Scrivens Breakdown of academic impact, for papers by Shu-Jun Chiu Breakdown of academic impact, for papers by Rossana La Sorda Breakdown of academic impact, for papers by William Y. Chang Breakdown of academic impact, for papers by Brad Saville Breakdown of academic impact, for papers by A. Yu. Grishanova Breakdown of academic impact, for papers by Daniela Montanaro
Rankless by CCL
2026